Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
JLARC: drug takeback fee cap and operator‑linked formula limit DOH oversight cost recovery; recommends fee redesign
Summary
JLARC's expedited review found Department of Health fee revenue did not cover oversight costs in FY2022–2025 and recommended removing the fee cap and the fee's linkage to program operator expenditures so DOH can recover program oversight costs more reliably.
A JLARC expedited preliminary report presented Jan. 7 found that the current statutory fee design for Washington’s drug takeback program limits the Department of Health’s ability to recover oversight costs and reduces transparency for stakeholders.
"The legislative auditor recommends that the legislature should amend the fee design to meet best practices and enable full cost recovery by DOH," JLARC staff member Amanda Edrick told the committee. JLARC reported that DOH’s oversight of the program cost between about $321,000 and $527,000 annually from fiscal years 2022 through 2025, while fee revenue tracked to operator expenditures and, since 2022, did not cover those…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
